Priority Area 7: Facilitate Development of Medical Countermeasures
FDA plays a pivotal role in protecting our nation from chemical, biological, radiological, and nuclear threats, and from emerging infectious diseases. FDA’s responsibility is to ensure that medical countermeasures (MCMs)—such as drugs, vaccines, and diagnostic tests—to counter these threats are safe, effective, and secure.
MCM-related research areas of interest under the BAA include:
- Develop, character, and qualify tools to support MCM development under the Animal Rule or Accelerated Approval
- Modernize tools to evaluate MCM product safety, efficacy, and quality, and secure the MCM supply chain
- Advance the development of tools to enable the rapid development and availability of investigational MCMs
- Enable development and evaluation of novel and improved materials and manufacturing methods
Extramural Research Funded through the BAA
- Cross-Species Immune System Reference
- Organs-on-Chips for Radiation Countermeasures
- Ensuring Appropriate Public Use of Medical Countermeasures through Effective Emergency Communication
- Investigating Decontamination and Reuse of Respirators in Public Health Emergencies
- Optimizing Respirator Decontamination to Ensure Supplies for Emergency Preparedness
- Streamlining Countermeasure Data Collection During Public Health Emergencies
- Hybrid Genome Sequencing and Assembly of Bacterial Pathogens Using Emerging Innovative Technologies
- Flu therapeutic area data standards development
- Melioidosis Modeling: Research to Support Countermeasures for a Tricky Pathogen
- Developing a Toolkit to Assess Efficacy of Ebola Vaccines and Therapeutics
- Supporting Field Laboratory Testing of Ebola Antibodies in Sierra Leone
- Survivor Studies: Better Understanding Ebola's After-Effects to Help Find New Treatments
- Comparison of Host Responses to Ebola Virus Disease (EVD)
- A new approach for understanding Ebola virus pathogenesis
- Characterizing immunity to Ebola and Marburg to support medical countermeasure development
- Human organ chips for radiation countermeasure development
- FDA and global partners to analyze coronavirus samples
- Cellular signaling and immune correlates for SARS-CoV-2 infection
- Expanding next-generation sequencing tools to support pandemic preparedness and response
- Strengthening coronavirus models with systems biology and machine learning
- Using real-world evidence to advance COVID-19 medical countermeasures
- Pediatric disease modeling for long COVID